News for Kodiak Sciences Inc. (KOD)

Kodiak Sciences (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PR NewswirePALO ALTO, Calif., May 29, 2025 PALO ALTO, Calif., May 29, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company

On March 31, 2025, BlackRock, Inc. (Trades, Portfolio) executed a significant reduction in its holdings of Kodiak Sciences Inc. The firm decreased its position

Kodiak Sciences (KOD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

PR NewswirePALO ALTO, Calif., March 27, 2025 PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent bu

We recently published a list of 10 Hot Biotech Stocks Under $5. In this article, we are going to take a look at where Kodiak Sciences Inc.

PR NewswirePALO ALTO, Calif., March 10, 2025 Topline clinical data of the confirmatory registrational study GLOW2 expected in 1Q 2026.GLOW2 study design mi

Kodiak Sciences uses a novel biopolymer conjugate platform to develop more durable, next-generation retinal disease therapies. Read why KOD stock is a Buy.

U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Tuesday. Shares of Polaris Inc. PII fell sharply in today's pre...

One of the strongest stock market anomalies is the momentum effect, which is the tendency of recent past winners to outperform the recent past losers.

PR NewswirePALO ALTO, Calif., Jan. 7, 2025 PALO ALTO, Calif., Jan. 7, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 300 points on Thursday. The Dow traded down 0.79% to 42,208.88 while ...

Shares of Rumble Inc.

CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from 'Idea to IND' (I to ITM), ranging from target validation and antibody discovery through preclinical research, today announced a collaboration with Kodiak Sciences Inc. (Nasdaq: KOD). This partnership aims to advance the discovery of novel multi-target antibodies to treat ophthalmic diseases, leveraging Nona's proprietary Harbour Mice® fully human antibody platform.

U.S. stocks were lower, with the Nasdaq Composite falling around 100 points on Monday. Shares of Pactiv Evergreen Inc. PTVE rose sharply during Monday's sessio...

Shares of Kodiak Sciences (KOD) rallied 32% Monday after Jefferies upgraded the stock to buy from hold, citing the company’s turnaround and upcoming catalysts. Read more here.

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

Kodiak Sciences to Present at Innovate Retina 2024

VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are...